YF-VAX 1 dose vials
Ended Awarded Last action
- Contract number
- SPE2DR26FRBX1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,591
Award facts
- Contract value 100% obligated
- $12,590.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,590.80 to DMS Pharmaceutical Group Inc. for YF-VAX (Yellow Fever Vaccine) in single-dose vials on January 27, 2026. This firm fixed-price delivery order, which has no set-aside designation, is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The vendor, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense medical facilities. The performance location is Park Ridge, Illinois, with an ultimate completion date of February 18, 2026.
This delivery order represents one of numerous purchase orders DMS Pharmaceutical Group has received from the DLA's Medical Supply Chain division since securing its PPV-G GEN V prime vendor contract in November 2025. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including vaccines, biologics, prescription medications, and medical consumables to support Department of Defense military healthcare operations globally. As one of multiple regional prime vendors under the $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group's demonstrated performance across diverse product categories positions it to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FRBX1?
SPE2DR26FRBX1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FRBX1 worth?
The government has obligated $12,591 on SPE2DR26FRBX1.
Is contract SPE2DR26FRBX1 an order under another contract?
Yes. SPE2DR26FRBX1 is a delivery order under SPE2DR25D9206, an indefinite delivery contract.
Was contract SPE2DR26FRBX1 competed?
The extent of competition for SPE2DR26FRBX1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award